PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Heart Journal

• Publication date

  2015-09-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/ehv174PMID 25971287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

  2015cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

  2015cited by this paper
• On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.

  2015cited by this paper
• Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

  2014cited by this paper
• Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

  2014cited by this paper
• Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.

  2014cited by this paper
• Lipid lowering with PCSK9 inhibitors

  2014cited by this paper
• Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

  2014cited by this paper
• Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

  2014cited by this paper
• PCSK9 Antibodies for the Treatment of Hypercholesterolemia

  2014cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

  2014cited by this paper
• Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

  2013cited by this paper
• PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

  2013influential reference
• Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

  2013cited by this paper
• Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease

  2013cited by this paper
• The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia

  2013cited by this paper
• Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

  2012cited by this paper
• Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

  2012influential reference
• PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.

  2012cited by this paper
• Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

  2012cited by this paper
• An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

  2012cited by this paper
• Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

  2012cited by this paper
• A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

  2011cited by this paper
• A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]

  2011cited by this paper
• Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk

  2011cited by this paper
• Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study.

  2011cited by this paper
• Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

  2010cited by this paper
• Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.

  2010cited by this paper
• PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.

  2010cited by this paper
• Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia

  2010cited by this paper
• A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo

  2010cited by this paper
• Atherosclerosis Risk in Communities (ARIC) Study

  2009cited by this paper
• PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

  2009cited by this paper
• Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels: The Coronary Artery Risk Development in Young Adults Study

  2009cited by this paper
• A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

  2009cited by this paper
• Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease.

  2009cited by this paper
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

  2008cited by this paper
• Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors.

  2008cited by this paper
• Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

  2008cited by this paper
• The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2*

  2008cited by this paper
• Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia.

  2008cited by this paper
• Clinical characterization and molecular mechanisms of statin myopathy

  2008cited by this paper
• Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

  2007cited by this paper
• Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice Published, JLR Papers in Press, January 22, 2007.

  2007cited by this paper
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*

  2007cited by this paper
• Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

  2006cited by this paper
• Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006influential reference
• LDL-apheresis therapy

  2006cited by this paper
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006cited by this paper
• Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk

  2006cited by this paper
• Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing

  2006cited by this paper
• Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

  2005influential reference
• Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

  2005cited by this paper
• Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

  2005cited by this paper
• Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting

  2005cited by this paper
• The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients

  2004cited by this paper
• NARC-1/PCSK9 and Its Natural Mutants

  2004cited by this paper
• Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.

  2004cited by this paper
• ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL

  2004cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper
• Functional characterization of Narc 1, a novel proteinase related to proteinase K.

  2003cited by this paper
• The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation

  2003cited by this paper
• Late-Breaking Clinical Trial Abstracts

  2002cited by this paper
• Precursor convertases in the secretory pathway, cytosol and extracellular milieu.

  2002influential reference

• The Relationship between PCSK9 and the Occurrence of Atherosclerosis in Patients with Systemic Lupus Erythematosus

  2026cites this paper
• Which is the optimal choice in lipid-lowering therapy for reducing major cardiovascular events? a network meta-analysis

  2025cites this paper
• ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver

  2025cites this paper
• Exploring the benefits of alirocumab as lipid-lowering therapy in people with diabetes and very high cardiovascular risk.

  2025cites this paper
• Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein

  2024cites this paper
• PCSK9 Monoclonal Antibodies Have Come a Long Way

  2024cites this paper
• PCSK9 in T-cell function and the immune response

  2024cites this paper
• Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®

  2024cites this paper
• Immune Homeostasis Maintenance Through Advanced Immune Therapeutics to Target Atherosclerosis.

  2024cites this paper
• Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9

  2024cites this paper
• Direct Impact of PCSK9 on SMC Senescence and Apoptosis: A New Focus in Cardiovascular Diseases

  2024cites this paper
• PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression

  2024cites this paper
• Cholesterol in colorectal cancer: an essential but tumorigenic precursor?

  2023cites this paper
• PCSK9 inhibitors: current status and emerging frontiers in lipid control

  2023influential citation
• Positioning of PCSK9 Inhibitors in hypercholesterolemia

  2023cites this paper
• Per1/Per2 double knockout transcriptome analysis reveals circadian regulation of hepatic lipid metabolism

  2023cites this paper
• Familial hypercholesterolemia, lipoprotein(a) and atherosclerosis.

  2023cites this paper
• Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Inversely Associated with N-Terminal Pro B-Type Natriuretic Peptide in Older Men and Women

  2022cites this paper
• How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

  2022cites this paper
• PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era

  2022cites this paper
• PCSK9: A emerging participant in heart failure.

  2022cites this paper
• Dammarane-type saponins with proprotein convertase subtilisin/kexin type 9 inhibitory activity from Gynostemma pentaphyllum.

  2021cites this paper
• Heart-gut axis: Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota

  2021cites this paper
• High Dietary Intervention of Lauric Triglyceride Might be Harmful to Its Improvement of Cholesterol Metabolism in Obese Rats.

  2021cites this paper
• [The triglyceride-lowering effects of PCSK9 inhibitor differ in patients with different baseline triglyceride levels].

  2020cites this paper
• Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study

  2020cites this paper
• Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure)

  2020cites this paper
• PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle‐Aged Population: The STANISLAS Cohort

  2020cites this paper
• Hydroxyurea Regressed Atherosclerosis Plaques in ApoE-/- mice: A Discovery Based on Clinic

  2020cites this paper
• Small molecules as inhibitors of PCSK9: Current status and future challenges.

  2019cites this paper
• Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina

  2019cites this paper
• Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.

  2019cites this paper
• PCSK9 is Expressed in Human Visceral Adipose Tissue and Regulated by Insulin and Cardiac Natriuretic Peptides

  2019cites this paper
• Eje PCSK9-receptor de LDL y resultados clínicos en la insuficiencia cardiaca: un subanálisis del estudio BIOSTAT-CHF

  2018cites this paper
• Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy

  2018cites this paper
• ‘The lower the better’ revisited: low-density lipoprotein and lipoprotein(a)

  2018cites this paper
• Advancement in nanotechnology-based approaches for the treatment and diagnosis of hypercholesterolemia

  2018cites this paper
• Evolocumab and Alirocumab: A Review of the Emerging Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in the Management of Hyperlipidaemia

  2018influential citation
• Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study

  2018cites this paper
• Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

  2017cites this paper
• Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

  2017cites this paper
• Circulating PCSK9 affects serum LDL and cholesterol levels more than SREBP-2 expression.

  2017cites this paper
• Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow

  2017cites this paper
• PCSK9 in chronic kidney disease

  2017cites this paper
• PCSK9: Regulation and Target for Drug Development for Dyslipidemia.

  2017cites this paper
• Modern prevention: genetic testing, vascular imaging, machine learning, and drug safety.

  2017cites this paper
• From Eisenhower’s heart attack to modern management: a true success story!

  2017cites this paper
• 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular–Cellular Mechanisms in the Progression of Atherosclerosis

  2017cites this paper
• Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination.

  2017cites this paper
• Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study

  2017cites this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data

  2017cites this paper
• Detection and treatment of atherosclerosis using nanoparticles.

  2017cites this paper
• Plaque burden, microstructures and compositions underachieving very low LDL-C levels

  2017cites this paper
• The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.

  2017cites this paper
• Effects of intensive LDL lowering on coronary atherosclerosis

  2017cites this paper
• PCSK9 e aterosclerosi: solo LDL colesterolo? = PCSK9 and atherosclerosis: effects beyond LDL cholesterol

  2017cites this paper
• PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM

  2017cites this paper
• Hipercolesterolemia familiar heterocigota en manejo con anti–PCSK9

  2017cites this paper
• Inhibidores de la paraproteína convertasa subtilisina/kexina tipo 9: una alternativa de manejo para las dislipidemias

  2017cites this paper
• Comprehensive efforts to increase adherence to statin therapy

  2017cites this paper
• PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges.

  2017cites this paper
• Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants

  2017cites this paper
• Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.

  2017cites this paper
• Cholesterol and Heart Failure: Is There an Important Connection?

  2017cites this paper
• Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.

  2017cites this paper
• University of Dundee The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure Bayes-Genis,

  2017cites this paper
• Targeting Inflammation in Primary Cardiovascular Prevention.

  2016cites this paper
• Prognostic value of PCSK 9 levels in patients with acute coronary syndromes

  2016cites this paper
• [Co-existence of cardiovascular risk factors in patients with diabetes and peripheral vascular disease].

  2016cites this paper
• Pharmacogenomics to Revive Drug Development in Cardiovascular Disease

  2016cites this paper
• Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

  2016cites this paper
• Oligonucleotide therapies for RNA and DNA : modulation of natural splice-variants, DNA structure & characterization of new synthetic nucleotides and reporter cell lines

  2016cites this paper
• Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.

  2016cites this paper
• Improving prevention: risk scores, imaging, and PCSK9 inhibitors.

  2016cites this paper
• Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?

  2016cites this paper
• Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation.

  2016cites this paper
• Inhibiteurs de la PCSK9 : un nouveau traitement pour l’hypercholestérolémie

  2016cites this paper
• The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease.

  2016cites this paper
• Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.

  2016cites this paper
• Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.

  2016cites this paper
• Lower might be better - It matters how you get there, and in whom.

  2016cites this paper
• Einfluss der Lipidstoffwechselparameter auf die Entstehung und Progression der koronaren Herzerkrankung

  2016cites this paper
• LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors.

  2016cites this paper
• A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition

  2016cites this paper
• LDL-Cholesterol: Standards of Treatment 2016: A German Perspective

  2016cites this paper
• The Year in Cardiology 2015: Prevention

  2016influential citation
• The future of lipid guidelines

  2016cites this paper
• A review of PCSK9 inhibition and its effects beyond LDL receptors.

  2016cites this paper
• Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

  2016influential citation
• Novel mechanisms of atherosclerosis and cardiovascular repair.

  2016cites this paper
• PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering.

  2016cites this paper
• Translational atherosclerosis research: From experimental models to coronary artery disease in humans.

  2016influential citation
• Alirocumab: A Review in Hypercholesterolemia

  2016influential citation
• Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.

  2016cites this paper
• Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience

  2016cites this paper
• PCSK9-Inhibitoren bei Hypercholesterinämie

  2016cites this paper
• Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids

  2016cites this paper
• Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options

  2016cites this paper
• LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.

  2016cites this paper
• Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France patient-oriented and epidemiological research

  2016cites this paper